Tesofensine for Stubborn Weight Management

Candidate profile

Adults with obesity (BMI ≥30 or ≥27 with comorbidities) who:

• Have not achieved adequate weight loss with GLP-1 agonists (semaglutide/tirzepatide) — either insufficient response (<5% weight loss at adequate doses) or intolerance (severe GI side effects)
• Have significant food reward/craving component to their eating behavior (dopaminergic component)
• Have normal baseline cardiovascular health (no uncontrolled hypertension, arrhythmias, or coronary artery disease)
• Understand the investigational nature of tesofensine (not FDA-approved)

Not appropriate for:

• Individuals with uncontrolled hypertension, tachycardia, or cardiac arrhythmias
• History of stimulant abuse or dependence
• Concurrent use of MAO inhibitors, other stimulants, or serotonergic medications (serotonin syndrome risk)
• Individuals who could achieve adequate results with FDA-approved options

Approach

Tesofensine is a triple monoamine reuptake inhibitor (serotonin + norepinephrine + dopamine) that addresses obesity through:

1. Appetite suppression: Serotonin and norepinephrine in hypothalamic feeding circuits
2. Increased energy expenditure: Norepinephrine-driven thermogenesis
3. Reduced food reward/craving: Dopamine in mesolimbic reward pathways

This triple mechanism distinguishes tesofensine from single-pathway agents and addresses the hedonic eating component that GLP-1 agonists may not fully control.

Protocol

Starting dose and titration

• Week 1–2: 0.25 mg daily (assess cardiovascular tolerance)
• Week 3–4: 0.5 mg daily (target dose for most individuals)
• Maximum: 0.5 mg (the 1.0 mg dose from Phase II trials showed unacceptable cardiovascular effects)

Timing: Morning administration (avoid evening dosing due to potential insomnia)

With food: Can be taken with or without food (not food-dependent like GLP-1s)

Duration: Continuous use under ongoing medical supervision

Cardiovascular monitoring protocol

This is non-negotiable due to tesofensine's sympathomimetic effects:

| Parameter | Frequency | Action Threshold |

|-----------|-----------|-----------------|

| Resting heart rate | Weekly × 4, then monthly | >100 bpm sustained or >15 bpm increase |

| Blood pressure | Weekly × 4, then monthly | >140/90 or >10 mmHg increase from baseline |

| ECG | Baseline + week 4 | New arrhythmia or QTc prolongation |

| Symptoms | Continuous self-monitoring | Palpitations, chest pain, dyspnea |

If thresholds exceeded: Reduce to 0.25 mg or discontinue. Do not exceed 0.5 mg in attempt to push through cardiovascular effects.

Adjunctive measures (required)

Tesofensine is not a standalone solution:

• Caloric deficit (500–750 kcal below maintenance)
• Resistance training (2–3× weekly) to preserve lean mass
• Protein intake ≥1.6 g/kg bodyweight
• Sleep optimization (tesofensine may affect sleep — manage proactively)

What to monitor

Primary outcomes

• Body weight: Weekly weigh-in (first morning, fasted)
• Waist circumference: Monthly (central adiposity is the metabolic-risk-relevant measure)
• Body composition: DEXA scan at baseline and 12 weeks (if available)

Metabolic markers (monthly)

• Fasting glucose and HbA1c
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Liver enzymes (ALT, AST)

Safety markers

• Blood pressure and heart rate (as above)
• Sleep quality assessment (insomnia is common with monoamine reuptake inhibitors)
• Mood assessment (dopamine/serotonin modulation can affect mood — positively or negatively)
• Dry mouth severity (most common side effect)

Timeline and expectations

Phase II data as reference

The TIPO-1 trial provides the best expectation calibrator:

• Placebo: 2.2% weight loss over 24 weeks
• 0.25 mg: 6.5% weight loss
• 0.5 mg: 12.8% weight loss
• 1.0 mg: 14.1% weight loss (unacceptable CV effects)

Realistic individual expectations

Weeks 1–4:

• Noticeable appetite suppression (especially reduced snacking and food preoccupation)
• 2–4% weight loss (partially water/glycogen)
• Possible side effects: dry mouth, constipation, mild insomnia
• Cardiovascular assessment period (confirm tolerability)

Weeks 4–12:

• Steady weight loss of 1–2% per month
• Reduced food reward responses (less hedonic eating)
• Improved energy (norepinephrine effect)
• Side effects typically stabilize

Weeks 12–24:

• Cumulative 8–13% weight loss in responders
• Metabolic markers improving (glucose, lipids)
• Weight loss rate may plateau (metabolic adaptation)

Non-response

If <3% weight loss after 8 weeks at 0.5 mg with adherence to caloric deficit:

• Confirm adherence to diet (caloric intake tracking)
• Consider that tesofensine mechanism may not address this individual's obesity phenotype
• Re-evaluate alternative approaches

Comparison with GLP-1 agonists

| Parameter | Tesofensine 0.5 mg | Semaglutide 2.4 mg | Tirzepatide 15 mg |

|-----------|-------------------|--------------------|-------------------|

| Weight loss (24 wk) | ~13% | ~10% (at 24 wk; ~15% at 68 wk) | ~15% (at 24 wk) |

| Mechanism | Triple reuptake inhibitor | GLP-1 receptor agonist | GLP-1/GIP dual agonist |

| Route | Oral (daily) | SubQ (weekly) | SubQ (weekly) |

| Main side effects | CV (HR, BP), dry mouth, insomnia | GI (nausea, vomiting, diarrhea) | GI (nausea, vomiting) |

| FDA approved | No | Yes (Wegovy) | Yes (Zepbound) |

| Muscle loss concern | Less (dopamine may be muscle-sparing) | Yes (30–40% lean mass loss) | Yes |

Key differentiators for tesofensine

1. Oral route: No injections (compliance advantage for needle-averse)
2. Dopamine component: Addresses food reward/craving that GLP-1s may miss
3. Less GI distress: Mechanism doesn't directly slow gastric emptying
4. Potential muscle-sparing: Catecholamine-driven metabolism may preferentially target fat

Key advantages of GLP-1s over tesofensine

1. FDA-approved: Regulatory validation, insurance coverage potential
2. Cardiovascular safety data: MACE reduction demonstrated (SELECT trial)
3. Multi-organ benefits: Hepatic, cardiovascular, renal protective effects
4. Long-term data: Multi-year outcome studies exist
5. No cardiac stimulation: Actually cardioprotective

Safety emphasis

Tesofensine's mechanism is fundamentally stimulatory (increasing catecholamines). This carries inherent cardiovascular risk that GLP-1 agonists do not share. The decision to use tesofensine should be made with full awareness of:

• No long-term (>24 week) safety data in obesity populations
• No cardiovascular outcome trials
• Mechanism similar to drugs withdrawn for CV safety (sibutramine)
• Requires ongoing cardiovascular monitoring

This use case represents a risk-aware choice by informed individuals who cannot tolerate or respond to safer first-line options — not a first-line recommendation.